Safety of Tedizolid as Suppressive ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.
Author(s) :
Ferry, T. [Auteur]
Conrad, A. [Auteur]
Senneville, Eric [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Roux, S. [Auteur]
Dupieux-Chabert, C. [Auteur]
Dinh, A. [Auteur]
Lustig, S. [Auteur]
Goutelle, S. [Auteur]
Briot, T. [Auteur]
Pham, T. T. [Auteur]
Valour, F. [Auteur]
Conrad, A. [Auteur]
Senneville, Eric [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Roux, S. [Auteur]
Dupieux-Chabert, C. [Auteur]
Dinh, A. [Auteur]
Lustig, S. [Auteur]
Goutelle, S. [Auteur]
Briot, T. [Auteur]
Pham, T. T. [Auteur]
Valour, F. [Auteur]
Journal title :
Open Forum Infectious Diseases
Abbreviated title :
Open Forum Infect Dis
Volume number :
8
Pages :
p. 1-6
Publication date :
2021-07
ISSN :
2328-8957
English keyword(s) :
bone and joint infection
linezolid
periprosthetic joint infection
suppressive antimicrobial therapy
tedizolid
linezolid
periprosthetic joint infection
suppressive antimicrobial therapy
tedizolid
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive ...
Show more >A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.Show less >
Show more >A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Submission date :
2023-11-15T06:07:21Z
2024-03-21T09:16:00Z
2024-03-21T09:25:14Z
2024-03-21T09:16:00Z
2024-03-21T09:25:14Z
Files
- ofab351.pdf
- Version éditeur
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States